Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martini, C.
Right arrow Articles by Bembi, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martini, C.
Right arrow Articles by Bembi, B.
Neurology 2001;57:906-908
© 2001 American Academy of Neurology
Brief Communications

Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2

C. Martini, MD;, G. Ciana, MD;, A. Benettoni, MD;, F. Katouzian, SD;, G. M. Severini, SD;, R. Bussani, MD; and B. Bembi, MD

From the Children’s Hospital "Burlo Garofolo" (Drs. Martini, Ciana, Benettoni, Katouzian, Severini, and Bembi) and Istituto di Anatomia Patologica (Dr. Bussani), University of Trieste, Italy.

Address correspondence and reprint requests to Dr. Bruno Bembi, Children’s Hospital "Burlo Garofolo," via dell’Istria 65/1, 34137 Trieste, Italy; e-mail: bembi{at}burlo.trieste.it

Glycogenosis type 2 is an autosomal recessive glycogen storage disorder caused by deficiency of lysosomal acid {alpha}-glucosidase. Different phenotypes are recognized. The authors describe two children affected by the late infantile form; both presented terminal hyperthermia not caused by infections. Autopsy performed in one case showed diffuse glycogen storage in the CNS neurons. In light of current interest in enzyme replacement therapy, this finding casts some doubt on how effective enzyme replacement therapy will be unless it can be targeted directly into the CNS.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
L. R. DeRuisseau, D. D. Fuller, K. Qiu, K. C. DeRuisseau, W. H. Donnelly Jr, C. Mah, P. J. Reier, and B. J. Byrne
Neural deficits contribute to respiratory insufficiency in Pompe disease
PNAS, June 9, 2009; 106(23): 9419 - 9424.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. Bembi, E. Cerini, C. Danesino, M. A. Donati, S. Gasperini, L. Morandi, O. Musumeci, G. Parenti, S. Ravaglia, F. Seidita, et al.
Management and treatment of glycogenosis type II
Neurology, December 2, 2008; 71(23_suppl_2): S12 - S36.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
E. Martin-Touaux, J.P. Puech, D. Chateau, C. Emiliani, E.J. Kremer, N. Raben, B. Tancini, A. Orlacchio, A. Kahn, and L. Poenaru
Muscle as a putative producer of acid {alpha}-glucosidase for glycogenosis type II gene therapy
Hum. Mol. Genet., July 1, 2002; 11(14): 1637 - 1645.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.